Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Personalized dendritic cell (DC) based vaccines offer promising immunotherapeutic approaches for cancers and infectious diseases by leveraging living DCs to stimulate a patient's immune system through interactions with T cells. However, conventional DC-based vaccines face significant challenges, including limited stability and short storage lifespan of the living cells. To overcome these limitations, smart artificial nanorobots, termed nano-bone marrow dendritic cell (BMDC)-originated T cell activators (nano-BOTs) are developed by incorporating 1-dimensional (1D) nanoparticles to enhance stability and activation efficacy. The use of 1D nanoparticles enables precise modulation of the geometric properties, resulting in significantly improved interactions with effector T cells. This innovative approach addresses the inherent limitations of traditional DC-based vaccines and amplifies their ability to activate effector T cells. The advanced nanorobots exhibit exceptional stability and therapeutic potential, representing a transformative step toward personalized DC-based vaccines in future biological therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147988 | PMC |
| http://dx.doi.org/10.1002/adhm.202500846 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of a Dendritic Cell Vaccine Loaded With Whole Tumor Antigen on Bladder Cancer Model in hu-PBL-SCID Mice.
Drug Dev Res
September 2025
Department of Urology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China.
The aim of this study was to establish a humanized immune system model in severe combined immunodeficient (SCID) mice, assess dendritic cell (DC) phenotype, and evaluate the therapeutic efficacy of a DC-based vaccine in a bladder cancer model. Bladder cancer was induced in SCID mice by injection of T24 cells, followed by human peripheral blood leukocyte (hu-PBL) inoculation to reconstitute the human immune system. DCs were generated in vitro by culturing hu-PBL for 5 days and matured on the eighth day.
View Article and Find Full Text PDFMechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective.
Front Immunol
September 2025
Department of Cardiology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, with only modest improvements in survival despite advances in conventional therapies. Cell-based immunotherapy, which utilizes ex vivo expanded or genetically modified immune cells, has emerged as a promising therapeutic alternative. Approaches such as natural killer (NK) cells, tumor-infiltrating lymphocytes (TILs), dendritic cell (DC)-based vaccines, cytokine-induced killer (CIK) cells, and chimeric antigen receptor T (CAR-T) cells have shown encouraging potential in preclinical and early clinical studies.
View Article and Find Full Text PDFImmune Responses of Dendritic Cells to Zoonotic DNA and RNA Viruses.
Vet Sci
July 2025
College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
Viral infections persistently challenge global health through immune evasion and zoonotic transmission. Dendritic cells (DCs) play a central role in antiviral immunity by detecting viral nucleic acids via conserved pattern recognition receptors, triggering interferon-driven innate responses and cross-presentation-mediated activation of cytotoxic CD8 T cells. This study synthesizes DC-centric defense mechanisms against viral subversion, encompassing divergent nucleic acid sensing pathways for zoonotic DNA and RNA viruses, viral counterstrategies targeting DC maturation and interferon signaling, and functional specialization of DC subsets in immune coordination.
View Article and Find Full Text PDFEnhancing DC cancer vaccine by allogeneic MHC class II expression and Treg depletion.
JCI Insight
August 2025
Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
We assessed the therapeutic efficacy of a semiallogeneic dendritic cell (DC) vaccine in comparison to a syngeneic one for suppression of B16-F10 and TC-1 tumors. Syngeneic bone marrow-derived DCs (BMDCs) were generated from C57BL/6J mice and semiallogeneic BMDCs with a mutation in either MHC class I or II were generated from B6.C-H2-Kbm1/ByJ or B6(C)-H2-Ab1bm12/KhEgJ mice, respectively.
View Article and Find Full Text PDFBiomimetic nanoimmunotherapy boosts spatiotemporal PANoptosis and reshapes desmoplastic tumor microenvironment.
Cell Rep Med
August 2025
Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai 200444, P.R. China; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou 325000, P.R. China; Shanghai Institute of Materdicine, Shanghai 200052, P.R. China. Electronic address: chenyuedu@
Dendritic cell (DC)-based vaccines for solid tumors face major challenges, including limited tumor-specific antigens and immunosuppressive stroma. Here, we present a therapeutic nanovaccine (UCNP@MOF@MI@FM [UMMF]) composed of a DC/tumor fused cytomembrane-coated UCNP@MOF nanoparticle, co-loaded with a MutT homolog 1 (MTH1) inhibitor and combined with tetrahydrobiopterin (BH4). The fused membrane facilitates dual targeting to tumors and lymph nodes while enabling broad-spectrum tumor antigen presentation.
View Article and Find Full Text PDF